Journal of Practical Hepatology ›› 2021, Vol. 24 ›› Issue (2): 301-304.doi: 10.3969/j.issn.1672-5069.2021.02.039
Wang Qiuyue, Guo Linqi, He Qiyong
Received:
2020-04-30
Online:
2021-03-10
Published:
2021-04-30
Wang Qiuyue, Guo Linqi, He Qiyong. Imaging diagnosis of hilar cholangiocarcinoma[J]. Journal of Practical Hepatology, 2021, 24(2): 301-304.
[1] Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology, 2011, 54(1):173-184. [2] Welzel Tania M,Graubard Barry I,El-Serag Hashem B, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.Pub Med,2007,5(10):213-217. [3] Yachimski P , Pratt D S . Cholangiocarcinoma: Natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol, 2008, 42(2):178-190. [4] Ijin J , Min L J , Hee Y J . Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: Recent advances and challenges. Radiology, 2018:171187-171192. [5] 黄强,杨骥,林先盛,等.CT三维重建在肝门部胆管癌的诊疗中的应用价值.中国普通外科杂志,2017,26(8):960-967. [6] 王祥宇, 陆录, 钦伦秀. 肝门部胆管癌临床治疗进展. 中华肝脏外科手术学电子杂志, 2018, 7(4):253-257. [7] 倪其泓, 张赟和, 陈炜, 等.Bismuth Ⅳ型肝门部胆管癌根治术. 中华消化外科杂志, 2016, 15(4):380-384. [8] Nagino M , Ebata T , Yokoyama Y , et al. Evolution ofsurgical treatment for perihilar cholangiocarcinoma: A single-center 34-year review of 574 consecutive resections. Ann Surg, 2012, 258(1):129-140. [9] Razumilava N , Gores G J . Cholangiocarcinoma. Lancet, 2014, 383(9935):2168-2179. [10] 李相成,江王杰.肝门部胆管癌诊治进展.腹部外科,2019,32(01):7-12. [11] Zen Y , Adsay N V , Bardadin K , et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria.Modern Pathol, 2007, 20(6):701-709. [12] Klempnauer J,Ridder G J,Werner M,et al. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Pub Med,1997,79(1):321-328. [13] Miyazaki M , Ito H , Nakagawa K , et al. Aggressive surgical approaches to hilar cholangiocarcinoma: Hepatic or local resection? Surgery, 1998, 123(2):1-136. [14] Alfredo G, Andrea R,Tommaso C, et al.Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. Pub Med,2009,33(6):421-428. [15] 石景森, 何平. 肝门部胆管癌的诊断. 肝胆外科杂志, 2001, (2):83-84. [16] Dong K, Wang G P .Hilar cholangiocarcinoma: Pathology and tumor biology. Front Med China, 2010, 4(4):371-377. [17] Burak K , Angulo P , Pasha T M , et al. Incidence andrisk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol, 2004, 99(3):523-526. [18] Boberg K M , Bergquist A , Mitchell S , et al. Cholangiocarcinoma in primary sclerosing cholangitis: Risk factors and clinical presentation. Scand J Gastroenterol, 2002, 37(10):1205-1211. [19] Lazaridis K N, Gores G J. Primary sclerosing cholangitis and cholangiocarcinoma. 2006, 26(1):42-51. [20] Charatcharoenwitthaya P , Enders F B , Halling K C , et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology, 2008, 48:341-347. [21] Blechacz B , Komuta M , Roskams T , et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol, 2011, 8(9):512-522. [22] Paul A , Kaiser G M , Molmenti E P , et al. Klatskintumors and the accuracy of the Bismuth-Corlette classification. Am Surg, 2011, 77(12):1695-1699. [23] Suarez-Munoz M A , Fernandez-Aguilar J L , Sanchez-Perez B , et al. Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol, 2013, 5(7):132. [24] 李相成, 冯勤超. 肝门部胆管癌的进展与争议. 临床肝胆病杂志, 2019(12):341-344. [25] 倪其泓,王坚.肝门部胆管癌诊断和治疗指南(2013版)的解读与思考.肝胆胰外科杂志,2015,27(6):450-454. [26] Oliveira I S , Kilcoyne A , Everett J M , et al. Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management. Abdom Radiol, 2017, 42(6):1637-1649. [27] Valls C , Ruiz S , Martinez L , et al. Radiological diagnosis and staging of hilar cholangiocarcinoma. World J Gastrointest Oncol, 2013(7):10-21. [28] Hann L E , Greatrex K V , Bach A M , et al. Cholangiocarcinoma at the hepatic hilus: sonographic findings. Am J Roentgenol, 1997, 168(4):985-989. [29] Xu H X , Chen L D ,Xie X Y , et al. Enhancement pattern of hilar cholangiocarcinoma: Contrast-enhanced ultrasound versus contrast-enhanced computed tomography. Eur J Radiol, 2009, 75(2):197-202. [30] Ruys A T , Beem B E V , Engelbrecht M R W , et al. Radiological staging in patients with hilar cholangiocarcinoma: A systematic review and meta-analysis. Brit J Radiol, 2012, 85(1017):1255-1262. [31] Lee H Y , Kim S H , Lee J M , et al. Preoperativeassessment of resectability of hepatic hilar cholangiocarcinoma: Combined CT and cholangiography with revised criteria1. Radiology, 2006, 239(1):113-121. [32] Aloia T A , Charnsangavej C , Faria S , et al. High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg, 2007, 193(6):1-706. [33] Lazaridis K N ,Gores G J . Cholangiocarcinoma. Gastroenterology, 2005, 128(6):1655-1667. [34] Feydy A , Vilgrain V , Denys A , et al. Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings. Am J Roentgenol, 1999, 172(1):73-77. [35] Choi B I , Lee J M , Han J K . Imaging of intrahepatic and hilar cholangiocarcinoma. Abdom Imaging, 2004, 29(5):548-557. [36] 朱云峰,李建生,马金良, 等.三维重建技术在肝门部胆管癌术前评估中的价值.中国普通外科杂志,2016,25(2):175-180. [37] Lee S S , Kim M H , Lee S K , et al. MR cholangiography versus cholangioscopy for evaluation of longitudinal extension of hilar cholangiocarcinoma. Gastrointest Endosc, 2002, 56(1):25-32. [38] Masselli G , Manfredi R , Vecchioli A , et al. MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings. Eur Radiol, 2008, 18(10):2213-2221. [39] Lee M G , Park K B , Shin Y M , et al. Preoperativeevaluation of hilar cholangiocarcinoma with contrast-enhanced three-dimensional fast imaging with steady-state precession magnetic resonance angiography: Comparison with intraarterial digital subtraction angiography. World J Surg, 2003, 27(3):278-283. [40] Matos C , Serrao E , Bali M A .Magnetic resonance imaging of biliary tumors. Magn Reson Imaging Clin North Am, 2010, 18(3):477-496. [41] Sun H Y , Lee J M , Park H S , et al. Gadoxetic acid-enhanced MRI with MR cholangiography for the preoperative evaluation of bile duct cancer. J Magnet Reson Imaging, 2013, 38(1):138-147. [42] Jhaveri K S , Hosseini-Nik H . MRI of cholangiocarcinoma. J Magnet Reson Imaging, 2014, 42(5):412-416. [43] 方驰华,刘允怡,曾宁, 等.肝门部胆管癌三维可视化精准诊治中国专家共识(2019版).中国实用外科杂志,2020,40(3):260-266. [44] Yoon J H , Lee S M , Kang H J , et al. Clinicalfeasibility of 3-dimensional magnetic resonance cholangiopancreatography using compressed sensing: Comparison of image quality and diagnostic performance. Investig Radiol, 2017, 52(10):1. [45] Kim J Y , Kim M H , Lee T Y , et al. Clinicalrole of \r, 18\r, F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: A prospective study compared with conventional imaging. Am J Gastroenterol, 2008, 103(5):1145-1151. [46] Joo I , Lee J M , Lee D H , et al. Preoperativeassessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: A prospective preliminary study. Radiology, 2016,53:152798. [47] Lee D H , Lee J M . Whole-body PET/MRI for colorectal cancer staging: Is it the way forward? J Magnet Reson Imaging, 2016,54:322-326. [48] Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangiti]. Hepatology, 2010, 51(2):416-419. [49] 殷晓煜.肝门部胆管癌术前行胆道引流术减轻黄疸的争议与策略.中华消化外科杂志,2018,43(3):229-232. [50] Soares K C , Kamel I , Cosgrove D P , et al. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. HepatobiliarySurg Nutrit,2014,53(1):18-34. [51] Chryssou E , Guthrie J A , Ward J , et al. Hilar cholangiocarcinoma: MR correlation with surgical and histological findings. Clin Radiol, 2010, 65(10):781-788. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||